Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors;Effets secondaires cutanés des nouvelles molécules anticancéreuses: Focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 1 PART 2, 2008, Pages 16-24

  Deslandres, M ^a   Sibaud, V ^a   Chevreau, C ^a   Delord, J P ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Anti angiogenic therapy; Cutaneous side effect; EGFR inhibitors; Multitarget tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMATINIB; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SORAFENIB; SUNITINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG ERUPTION; HUMAN; REVIEW; ARTICLE; CANCER GROWTH; CANCER THERAPY; DRUG INHIBITION; PATHOPHYSIOLOGY; SKIN MANIFESTATION; SKIN TOXICITY; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; HUMANS; INDOLES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 42949160079     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(08)70093-0     Document Type: Article

References (50)

1. Grünwald V, Hidalgo M. Developing Inhibitors of the Epidermal Growth Factor Receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-67. (Pubitemid 36833877)
2. Adams JP, Veiner L. Monoclonal Antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
3. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006;22:152-62. (Pubitemid 44163102)
4. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500. (Pubitemid 40903630)
5. Segaert S, Van Custem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33. (Pubitemid 41222414)
6. Agero AL, Dusza S, Benvenuto-Andrade C, Busam C, Myskowsky P, Halpern A. Dermatologic side effects associated with epidermal growth factor receptor inhibitor. J Am Acad Dermatol 2006;55:657-70. (Pubitemid 44436627)
7. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006;55:429-37. (Pubitemid 44189595)
8. Cowen EW. Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol 2007;56:514-7. (Pubitemid 46273855)
9. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash : future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56. (Pubitemid 40647253)
10. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21. (Pubitemid 350012125)
11. Molinari E, De Quatrebarbes J, André T, Aractingi S. Cetuximab induced acne. Dermatology 2005;211:330-3.
12. De witt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor -targeted chemotherapy. J Am Acad Dermatol 2007;56:500-5. (Pubitemid 46273854)
13. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-51. (Pubitemid 41415923)
14. Hu JC, Sadeghi P, Pinter-brown LC, Yashar S, Chu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-26. (Pubitemid 46091817)
15. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR - targeted agents : is there a silver lining? J Clin Oncol 2005;23:5235-46. (Pubitemid 46224035)
16. Guillot B, Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l'EGF. Ann Dermatol Venereol 2006;133:1017-20. (Pubitemid 46018321)
17. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. Review. J Am Acad Dermatol 2007;56:460-5. (Pubitemid 46273839)
18. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76. (Pubitemid 34204207)
19. Suh KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 2006;154:191-2. (Pubitemid 43381348)
20. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006;1:1040-1. (Pubitemid 47181376)
21. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-6.
22. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
23. Bonner JA, Kian Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 2007;357:1872. (Pubitemid 350044823)
24. Bernier J, Bonner J, Vermoken JB, Arzanian N, Shin DM, Cohen RB et al. Consensus guidelines for the management of radiation dermatitis ad coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2007;Sep 4;[Epub ahead of print] ahead of print].
25. Gerber BA, Enderlein E, Homey B, Muller A, Boelke E, Budach W. Radiation-Induced Prevention of Erlotinib-Induced Skin Rash Is Transient: A New Aspect Toward the Understanding of Epidermal Growth Factor Receptor Inhibitor- Associated Cutaneous Adverse Effects. J Clin Oncol 2007;25:4697-8. (Pubitemid 350035339)
26. Mitra S, Simcock R. Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field. J Clin Oncol 2006;24:e28-9.
27. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80. (Pubitemid 34879334)
28. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-06. (Pubitemid 36232317)
29. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutanous side effects of imatinib mesylate. J Drug Dermatol 2006;5:228-31.
30. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-3. (Pubitemid 40175315)
31. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of three cases. J Am Acad Dermatol 2005;53:s240-3. (Pubitemid 41443480)
32. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 2006;45:1471-3. (Pubitemid 44869776)
33. ®). Ann Dermatol Venereol 2004;131:517-8. (Pubitemid 38796828)
34. Ramar K, Potti A, Mehdi SA. Periorbital oedema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol 2003;21:172-325.
35. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7. (Pubitemid 37466664)
36. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002;347:446.
37. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC) : Results of a Phase III randomized placebo -controlled trial (SHARP trial). ASCO 2007.
38. Escudie B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;15;13:1801-9. (Pubitemid 46952949)
39. Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12:1178-82. (Pubitemid 350106348)
40. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006;24:5786-8. (Pubitemid 46631323)
41. Yang CH, Lin WC, Chunag CK. Hand-foot skin reaction in patients treated with sorafenib : a clinicopathological stuy of cutaneous manifestations due to multitargeted kinase inhibitors therapy. Br J Dermatol 2007 (epud ahead of print).
42. Robert C. Effets secondaires cutanés des molécules anti-angiogéniques. Bull Cancer 2007;94:s260-4. (Pubitemid 47401369)
43. Tunc SE, Ertam I, Pirildar T, Turk T, Ozturk M, Doganavsargil E. Nail changes in connective tissue diseases: do nail changes provide clues for the diagnosis? J Eur Acad Dermatol Venereol 2007;21:497-503. (Pubitemid 46454903)
44. Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungueal splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005;143:313-4. (Pubitemid 41134231)
45. Barete S, Billemont B, Meric JB, Moguelet P, Francès C. Effets secondaires cutanés du sunitinib: étude prospective, chez 40 patients. Journées Dermatologiques de Paris (C61). Ann Dermatol Venereol 2007.
46. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006;31:783-5. (Pubitemid 44563396)
47. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-2.
48. Kong HH, Sibaud V, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol, 2008 (in press).
49. Mac Gregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad dermatol 2007;56:527-8. (Pubitemid 46273859)
50. Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, et al. Sorafenib: atypical cutaneous side effects. Eur J Dermatol 2007;17:549-50. (Pubitemid 350207179)